Cargando…

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Background: Treatment of rheumatoid arthritis (RA) includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs) and oral, intramuscularly, intravenous, or intraarticular (IA) glucocorticoids (GCs). In this paper, we analysed whether a treat-to-target (T2T) stra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Ruediger B., Spaeth, Michael, von Restorff, Cord, Ackermann, Christoph, Schulze-Koops, Hendrik, von Kempis, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462919/ https://www.ncbi.nlm.nih.gov/pubmed/30832414 http://dx.doi.org/10.3390/jcm8030302

Ejemplares similares

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis
por: Wennink, Roos A. W., et al.
Publicado: (2022)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
por: Nozaki, Yuji
Publicado: (2021)

Erratum: Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Publicado: (2017)

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs
por: Daraghmeh, Dala N, et al.
Publicado: (2022)

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study
por: Iwamoto, Naoki, et al.
Publicado: (2022)

Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients
por: Sun, Zhijian, et al.
Publicado: (2022)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors
por: İNANÇ, Güzide Nevsun, et al.
Publicado: (2023)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience
por: Xie, Wenhui, et al.
Publicado: (2023)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews: a cross-sectional study in China
por: Sun, Jiaying, et al.
Publicado: (2020)

Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database
por: Zanetti, Anna, et al.
Publicado: (2023)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
por: Genovese, Mark C., et al.
Publicado: (2020)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Is symptom duration before DMARD therapy a determinant of direct and indirect costs in DMARD-naïve RA patients? A systematic review
por: Sahbudin, Ilfita, et al.
Publicado: (2023)

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial
por: Väänänen, Tuija, et al.
Publicado: (2017)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
por: Jawad, Issrah I., et al.
Publicado: (2022)

Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan
por: Chen, Der-Yuan, et al.
Publicado: (2019)

Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials
por: Deng, Guoqian, et al.
Publicado: (2023)

A history of the term “DMARD”
por: Buer, Jonas Kure
Publicado: (2015)

INADEQUATE IMMUNE RESPONSE TO COVID-19 VACCINES IN THE PRESENCE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)
por: KRISHNAIAH, AISHWARYA, et al.
Publicado: (2022)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
por: Lukas, Cédric, et al.
Publicado: (2019)

Development of prediction model for alanine transaminase elevations during the first 6 months of conventional synthetic DMARD treatment
por: Kuusalo, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_51ccrvtd15clchu4ldbuv4bk8f